FT 1050

Drug Profile

FT 1050

Alternative Names: 16, 16 dimethyl-prostaglandin E2; dmPGE2; FT1050; ProHema; ProHema-CB; Prostaglandin E2 - Fate Therapeutics

Latest Information Update: 22 Jun 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Childrens Hospital Boston; Massachusetts General Hospital
  • Developer Fate Therapeutics
  • Class Antineoplastics; Chemoprotectants; Prostaglandins; Small molecules
  • Mechanism of Action Stem cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stem cell mobilisation
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Stem cell mobilisation

Most Recent Events

  • 11 Apr 2016 Fate Therapeutics terminates a phase-I trial in Stem cell mobilisation (In infants, In children, In adolescents with haematological malignancies) in USA (IV) (NCT02354417)
  • 11 Apr 2016 Fate Therapeutics terminates a phase I trial for Stem cell mobilisation (in paediatric patients with metabolic disorders) in USA (NCT02354443)
  • 03 Mar 2016 Discontinued - Phase-I for Stem cell mobilisation (In adolescents, In children, In infants) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top